Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation

Thrombosis and Haemostasis

Volumn 108, Issue 6, 2012, Pages 1132-1140

  Xu, Qiang ^a   Xu, Bin ^a   Zhang, Yuxiao ^a   Yang, Jie ^a   Gao, Lei ^a   Zhang, Yan ^a   Wang, Hongjuan ^a   Lu, Caiyi ^a   Zhao, Yusheng ^a   Yin, Tong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Dosing algorithm; Low intensity anticoagulation; Pharmacogenetics; Warfarin

Indexed keywords

WARFARIN;

ADULT; ALGORITHM; ANTICOAGULATION; ARTICLE; CARDIOMYOPATHY; CHINESE; COHORT ANALYSIS; COMORBIDITY; DEEP VEIN THROMBOSIS; DNA EXTRACTION; FEMALE; GENETIC ANALYSIS; GENOTYPE; GENOTYPING TECHNIQUE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHARMACOGENETIC REFINEMENT ALGORITHM; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; WARFARIN;

EID: 84871427116     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-05-0362     Document Type: Article

References (50)

1. Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 2006; 62: 509-511.
2. Budnitz DS, Pollock DA, Weidenbach KN, et al. National surveillance of emergency department visits for outpatient adverse drug events. J Am Med Assoc 2006; 296: 1858-1866.
3. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 2002; 287: 1690-1698.
4. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
5. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-792.
6. Carlquist JF, Anderson JL. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation 2011; 124: 2554-2559.
7. Lubitz SA, Scott SA, Rothlauf EB, et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost 2010; 8: 1018-1026.
8. Wu AH, Wang P, Smith A, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008; 9: 169-178.
9. Sagreiya H, Berube C, Wen A, et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics 2010; 20: 407-413.
10. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 2010; 87: 572-578.
11. Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 2010; 12: 125-134.
12. Roper N, Storer B, Bona R, et al. Validation and comparison of pharmacogeneticsbased warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn 2010; 12: 283-291.
13. Suzuki S, Yamashita T, Kato T, et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J 2007; 71: 761-765.
14. Dong L, Shi YK, Tian ZP, et al. Low intensity anticoagulation therapy after mechanical heart valve replacement. Zhonghua Wai Ke Za Zhi 2003; 41: 250-252.
15. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-1188.
16. You JH, Chan FW, Wong RS, et al. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005; 59: 582-587.
17. Haibo Z, Jinzhong L, Yan L, et al. Low-intensity international normalized ratio (INR) oral anticoagulant therapy in Chinese patients with mechanical heart valve prostheses. Cell Biochem Biophys 2012; 62: 147-151.
18. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-1434.
19. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011; 90: 625-629.
20. Liu Y, Yang J, Xu Q, et al. Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients. Thromb Res 2012; Epub ahead of print.
21. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-331.
22. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-4112.
23. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5: e1000433.
24. Yin T, Maekawa K, Kamide K, et al. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008; 31: 1549-1557.
25. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
26. Tham LS, Goh BC, Nafziger A, et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 2006; 80: 346-355.
27. Miao L, Yang J, Huang C, et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007; 63: 1135-1141.
28. Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007; 120: 181-186.
29. Wen MS, Lee M, Chen JJ, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008; 84: 83-89.
30. Lee MT, Chen CH, Chou CH, et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 2009; 10: 1905-1913.
31. Ohno M, Yamamoto A, Ono A, et al. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol 2009; 65: 1097-1103.
32. Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009; 19: 226-234.
33. Harada T, Ariyoshi N, Shimura H, et al. Application of Akaike information criterion to evaluate warfarin dosing algorithm. Thromb Res 2010; 126: 183-190.
34. You JH, Wong RS, Waye MM, et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis 2011; 31: 113-118.
35. Choi JR, Kim JO, Kang DR, et al. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J Hum Genet 2011; 56: 290-295.
36. Wei M, Ye F, Xie D, et al. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: Derivation in Han Chinese patients with non valvular atrial fibrillation. Thromb Haemost 2012; 107: 1083-1091.
37. Liang R, Li L, Li C, et al. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. J Thromb Thrombolysis 2012; 34: 120-125.
38. Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives. Thromb Res 2007; 120: 1-10.
39. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
40. Li C, Schwarz UI, Ritchie MD, et al. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 2009; 113: 3925-3930.
41. Ferder NS, Eby CS, Deych E, et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 2010; 8: 95-100.
42. Millican EA, Lenzini PA, Milligan PE, et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007; 110: 1511-1515.
43. Lenzini PA, Grice GR, Milligan PE, et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost 2008; 6: 1655-1662.
44. Chan SL, Goh BC, Chia KS, et al. Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multi-ethnic Asian population. Thromb Haemost 2011; 105: 1100-1102.
45. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 2010; 115: 3827-3834.
46. Rosove MH, Grody WW. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann Intern Med 2009; 151: 270-273, W295.
47. Johnson EG, Horne BD, Carlquist JF, et al. Genotype-based dosing algorithms for warfarin therapy: data review and recommendations. Mol Diagn Ther 2011; 15: 255-264.
48. Horne BD, Lenzini PA, Wadelius M, et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost 2012; 107: 232-240.
49. French B, Joo J, Geller NL, et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 2010; 11: 108.
50. Do EJ, Lenzini P, Eby CS, et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J 2011; epub ahead of print doi:10.1038/tpj.2011.18.